Search results
Dr. Flanigan is a pediatric neurologist and neuromuscular specialist at Nationwide Children's Hospital and a professor at The Ohio State University. He is a leading researcher and clinician in gene therapy for inherited neuromuscular diseases, such as Duchenne muscular dystrophy and Sanfilippo syndrome.
Kevin Flanigan, MD, leads the Flanigan Lab, which studies inherited neuromuscular diseases and develops therapies. The lab focuses on dystrophinopathies, giant axonal neuropathy, and other rare and common neurologic syndromes.
Kevin M. Flanigan, M.D. Director, Center for Gene Therapy. Nationwide Children's Hospital Center for Gene Therapy, WA4023 700 Children's Drive Columbus, OH 43209. Phone: (614) 355-2947 Fax: (614) 722-3273 Email: kevin.flanigan@nationwidechildrens.org . Education & Training: University of Illinois, Urbana/Champaign, 1986 B.M. in Trumpet Performance
Mar 31, 2023 · Recently, at the 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, March 19-22, in Dallas, Texas, Kevin Flanigan, MD, gave a talk on the safety issues and concerns of gene therapies in neuromuscular diseases in a session on updates in gene therapy.
Kevin Flanigan, MD is a leading expert in neuromuscular disorders and gene therapy at Nationwide Children's Hospital. He will present on the cutting edge of research and RNA-targeted therapeutics for Duchenne muscular dystrophy at the 2023 FUTURES conference.
Kevin M. Flanigan, MD. Neurology. 700 Children's Dr. Columbus, OH 43205. (614) 722-4625. Principal Investigator. Lindsay N Alfano, PT, DPT, PCS. Center for Gene Therapy. Lindsay N Alfano, PT, DPT, PCS. Center for Gene Therapy. 700 Children's Drive. Columbus, OH 43205. (614)722-4515. Allison M Bradbury, PhD. Center for Gene Therapy.
Kevin Flanigan is a molecular neurobiologist who studies genotype/phenotype correlations in muscular dystrophies. He works on gene therapy approaches using AAV vectors and exon skipping to ameliorate symptoms.
